Visão geral da empresa
A clinical stage specialty pharmaceutical company, PRF Technologies Ltd., focuses on the reformulation of established therapeutics to provide extended periods of post-surgical pain relief specifically within the Israeli market. The firm develops PRF-110, a viscous clear oil-based solution designed to be instilled directly into surgical sites to manage pain effectively. This entity operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on developing niche medications rather than mass-market commodities. The company's scale is currently defined by a market capitalization of $1.98M and an annual revenue of $17,000 over the trailing twelve months, while the number of employees is not disclosed in available records. These financial figures indicate that the company operates with a very small market capitalization relative to its reported revenue, suggesting a micro-cap status where valuation metrics often diverge significantly from traditional large-cap standards. The disparity between a $1.98M market cap and $17,000 in revenue highlights the speculative nature of the valuation, as the market price does not directly correlate with current cash generation at this stage of development.
Saúde financeira
The company reported revenue of $17,000 for the trailing twelve months, yet it simultaneously recorded a net income of $-4,838,000 and an EBITDA of $-4,348,000, revealing a substantial gap between top-line activity and profitability. This significant negative income relative to minimal revenue indicates an aggressive cost structure or heavy investment in research and development expenses that have not yet been offset by commercial earnings. The free cash flow stands at $-2,002,250, which signifies that the company is burning through cash reserves to fund its operations and product development lifecycle. Currently, the firm holds $4.14M in cash assets against a negligible debt load of $21,000, providing a liquidity buffer that allows for continued operations despite the lack of current profitability. The balance sheet composition, reflected by a debt-to-equity ratio of 0.23, suggests a conservative leverage profile with minimal fixed obligations compared to equity. Furthermore, the current ratio of 1.78 indicates that the company possesses sufficient current assets to cover its short-term liabilities, pointing to adequate short-term liquidity management. Return on Equity is reported at -90.4% and Return on Assets at -38.7%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business. These negative return figures are typical for pre-revenue or early-stage clinical companies but highlight the capital intensity required to reach commercialization milestones.
Avaliação de valorização
The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is listed at -0.19, implying that the market is pricing in future earnings expectations that are currently negative or undefined. The price-to-book ratio stands at 0.23, indicating that the market values the company at a fraction of its book value, which suggests a lack of market premium or potentially undervaluation relative to its net asset position. Alternative valuation metrics such as the price-to-sales ratio of 116.25 and an EV/EBITDA of 0.32 suggest that the valuation is heavily reliant on revenue multiples rather than earnings, a common characteristic for companies with high growth potential but current losses. The 52-week price range spans from a low of $1.80 to a high of $17.95, meaning the current trading position fluctuates within this wide band depending on market sentiment and clinical trial updates. The beta value of 0.71 indicates that the stock price exhibits lower volatility relative to the broader market, moving less than 1.0 times the market index during periods of standard market fluctuation. Investors must interpret these metrics with caution, as the high price-to-sales multiple is not supported by current profitability, reflecting the high risk associated with investing in clinical stage pharmaceuticals.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue at this specific moment. Consequently, the company does not currently distribute a dividend, evidenced by a dividend yield of not available and a payout ratio of 0.0%, meaning the firm reinvests all available earnings and cash reserves into operational growth and clinical development rather than returning capital to shareholders. The absence of a dividend policy is consistent with the company's life-cycle stage, where capital retention is prioritized to fund the reformulation of therapeutics and the development of PRF-110. Overall, the growth and income profile is characterized by a lack of current profitability and dividend income, relying entirely on the potential for future commercial success to generate returns once the product achieves market penetration. The company's financial strategy focuses on bridging the gap between the current negative earnings and future positive cash flow generation necessary to sustain operations and expand market presence.